Posts

Showing posts with the label R&D Facilities

Subscribe Now!

Syngene International Ltd. FY2020-21 Annual Report Key Takeaways

Image
Syngene International Ltd. FY2020-21 Annual Report Key Takeaways  In continuation of my previous blog here is the updated version l ink to Initial Blog -  https://myweekendspot.blogspot.com/2020/10/syngene-next-giant-player-for-cdmo.html Company Overview Incorporated in 1994 as a subsidiary of Biocon, Syngene International (SIL) is a leading contract research organization (CRO), which supports R&D programs of global innovative companies.   SIL offers outsourced services to support discovery and development for organizations across industrial sectors like pharmaceuticals, biopharmaceuticals, nutraceuticals, animal health, agrochemicals, etc. It currently caters to 400+ global players including Bristol-Myers Squibb (BMS), Abbott, Baxter, and Amgen, among others. SIL derives 95% of its revenues from exports.   Syngene continued to build on its integrated drug discovery and development portfolio during the year, including a five-year collaboration with 3DC, the drug discovery

Dishman Carbogen Amcis - Fully Integrated CRAMS Player

Image
Dishman Carbogen Amcis  - Company Overview Twitter Handle: @shuchi_nahar Company Profile   Incorporated in 1983, Dishman Carbogen  Amcis  Limited (DCAL) started out as a manufacturer of quaternary ammonium and phosphate compounds. Having ventured into the CRAMS space in India, the company soon became one of the fastest growing companies. Today, company is a leading global outsourcing partner for the pharmaceutical industry,  offering  a portfolio of development, scale-up, and manufacturing services.   Company is a fully integrated CRAMS player working with global pharmaceutical innovators. Company has a global presence with development and manufacturing facilities across Europe, India, and China. Company provides end-to-end, integrated, high-value, niche CRAMS  offering , right from process research & development to late-stage clinical and commercial manufacturing facilities along with the supply of Active Pharmaceutical Ingredients (API) to innovator pharmaceutical companies.   De